Vanda Pharmaceuticals Inc.
VNDA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $102 | $136 | $135 | $52 |
| Short-Term Investments | $272 | $252 | $332 | $381 |
| Receivables | $47 | $34 | $34 | $32 |
| Inventory | $2 | $1 | $1 | $1 |
| Other Curr. Assets | $15 | $9 | $18 | $12 |
| Total Curr. Assets | $439 | $433 | $519 | $478 |
| Property Plant & Equip (Net) | $13 | $9 | $11 | $12 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $114 | $121 | $19 | $20 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $81 | $75 | $74 | $75 |
| Other NC Assets | $9 | $10 | $11 | $8 |
| Total NC Assets | $217 | $215 | $115 | $115 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $656 | $648 | $634 | $594 |
| Liabilities | – | – | – | – |
| Payables | $3 | $7 | $13 | $1 |
| Short-Term Debt | $4 | $2 | $2 | $2 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $92 | $78 | $76 | $71 |
| Total Curr. Liab. | $100 | $88 | $91 | $74 |
| LT Debt | $8 | $7 | $9 | $10 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $10 | $9 | $7 | $4 |
| Total NC Liab. | $18 | $16 | $16 | $14 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $12 | $9 | $11 | $12 |
| Total Liabilities | $118 | $104 | $107 | $89 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$174 | -$155 | -$158 | -$164 |
| AOCI | $0 | -$0 | -$1 | -$0 |
| Other Equity | $713 | $700 | $686 | $669 |
| Total Equity | $539 | $545 | $527 | $505 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $656 | $648 | $634 | $594 |
| Net Debt | -$90 | -$126 | -$124 | -$40 |